证据缺失等同于疗效缺失:TAVI常规使用脑栓塞保护装置的系统评价
结果显示CEP对全因卒中(RR 0.94,95%CrI 0.72-1.25)和致残性卒中(RR 0.76,95%CrI 0.44-1.23)均未达到临床相关阈值(ARD 1.1%),CEP临床有效概率<1%。结论认为现有CEP装置无法将TAVI围术期卒中风险降至临床相关程度。
要点
- CEP对全因卒中的RR为0.94(95%CrI 0.72-1.25),未达临床相关阈值。
- CEP对致残性卒中的RR为0.76(95%CrI 0.44-1.23),临床有效概率<1%。
- 现有CEP装置降低TAVI围术期卒中风险未达临床相关程度。
核心结论
- 现有CEP装置无法将TAVI围术期卒中风险降低至临床相关程度,未来相关试验可能无意义。
研究设计与样本
- 采用分层贝叶斯荟萃分析,基于对数相对风险(RR)尺度,并转换为绝对风险差异(ARD)和需治疗人数(NNT)。
主要发现
- 对照组全因卒中和致残性卒中的发生率分别为2.9%和1.4%。
- 全因卒中的中位RR为0.94(95%CrI 0.72-1.25),平均ARD为-0.17%(NNT 588),CEP具有临床相关效应的后验概率<1%。
- 致残性卒中的中位RR为0.76(95%CrI 0.44-1.23),平均ARD为-0.36%(NNT 278),CEP具有临床相关效应的后验概率<1%。
关键数值与推荐
- 临床相关性阈值基于已发表的专家共识,设定为ARD 1.1%(NNT 91)。
临床怎么用
- 不推荐在TAVI中常规使用现有CEP装置以降低围术期卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This updated hierarchical Bayesian meta-analysis aims to integrate the latest randomised controlled trials (RCTs) on the use of cerebral embolic protection (CEP) in transcatheter aortic valve implantation (TAVI) into previously available data, providing a definite answer to the clinical effectiveness of CEP in TAVI patients. METHODS: A systematic search was updated on 31 March 2025. RCTs were included when comparing transfemoral TAVI with use of CEP versus transfemoral TAVI without CEP. The primary outcome was all stroke, while the secondary outcome was disabling stroke. A hierarchical Bayesian meta-analysis was performed on the (log) relative risk (RR) scale and transformed to absolute risk differences (ARDs) and numbers needed to treat (NNTs). The threshold for clinical relevance was based on published expert consensus and established on 1.1% ARD (NNT 91). RESULTS: The study was updated with one new RCT, totalling a number of eight RCTs (n=11 590, CEP n=5921 patients, control n=5669 patients). The prevalence of all stroke and disabling stroke was 2.9% and 1.4% in the control group. The median RR for all stroke was 0.94 (95% credible interval (CrI) 0.72-1.25), translating to a mean of -0.17% ARD (NNT 588), and a posterior probability of a clinically relevant CEP effect of <1%. The median RR for disabling stroke was 0.76 (95% CrI 0.44-1.23), translating to a mean of -0.36% ARD (NNT 278), and a posterior probability of a clinically relevant CEP effect of <1%. CONCLUSION: Current-generation CEP devices are ineffective in reducing periprocedural TAVI-stroke risk to a clinically relevant degree, rendering future trials with these devices futile. PROSPERO REGISTRATION NUMBER: CRD42023407006.
引用
- Heuts S, Kawczynski MJ, Maesen B, et al. When absence of evidence equates to evidence of absence: the case of routine use of cerebral embolic protection devices in transcatheter aortic valve implantation. Heart. 2025. PMID: 40500116. doi:10.1136/heartjnl-2025-326208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。